Skip to main content

Featured

Daily Markets Update: TSX Rebounds, Europe Hits a Record, Nvidia Shock Rattles Asia (Nov. 12)

  CANADIAN MONEY BRIEF · DAILY MARKETS UPDATE Thursday, November 12, 2026 · Covers Wednesday’s close and Thursday’s Asian session Markets got their AI swagger back on Wednesday — and then Nvidia took some of it away overnight. A strong CoreWeave report lifted tech, pushed the S&P/TSX Composite higher and sent Europe to a record close, but reports that Nvidia’s board is weighing whether to remove CEO Jensen Huang rattled Asian chip stocks on Thursday and pointed U.S. futures lower. AT A GLANCE TSX: +0.67% to 36,411.72, recovering part of Tuesday’s hot-inflation drop. Wall Street: S&P 500 +1.31%, Nasdaq +1.60%, Dow +0.49% as CoreWeave revived the AI trade. Europe: STOXX 600 and Germany’s DAX both closed at records. Asia (Thursday): Taiex -2.63%, Nikkei -0.70% on Nvidia leadership worries. Gold slipped under US$4,000 on a firmer U.S. dollar; oil rebounded from two-month lows. Canada: TSX Claws Back Tuesday’s Loss The S&P/TSX Composite rose 241.27 points, or 0.67%, to...

article

Federal Government Boosts Vaccine Injury Compensation Fund with Additional $36 Million

 

The Canadian federal government has recently allocated an additional $36.4 million to the Vaccine Injury Compensation Fund, a program designed to support individuals who have experienced serious injuries or fatalities related to vaccines since the end of 2020. Here are the key details:

  1. Purpose of the Fund:

    • The program was established shortly after COVID-19 vaccines became available to the public.
    • It provides financial compensation to people who suffered adverse effects due to Health Canada-approved vaccines.
    • The goal is to assist those who were seriously impacted by vaccination.
  2. Funding and Administration:

    • The Liberal government initially earmarked $75 million for the first five years of the program.
    • A private firm called OXARO manages the program and disburses valid claims originating outside of Quebec.
    • To date, OXARO has received $56.2 million from Ottawa and has paid out $11.2 million in compensation.
    • Quebec has its own vaccine injury compensation program, which received $7.75 million when the federal program launched.
  3. Recent Funding Boost:

    • As part of the federal budget, the government allocated an additional $36 million to OXARO and Quebec.
    • This funding covers the next two years of the program.
    • The Public Health Agency of Canada contracted OXARO to ensure an impartial claims process.
  4. Eligibility and Claims:

    • The program covers injuries and deaths associated with vaccines approved for any illness.
    • Eligibility criteria include severe, life-threatening, or life-altering injuries resulting in disability, incapacity, birth defects, or death.
    • The available statistics do not specify which vaccines were involved.
  5. Rare Adverse Reactions:

    • Serious adverse reactions to vaccines are extremely rare (affecting less than one in a million people).
    • Nevertheless, the government recognizes its duty to provide support when such reactions occur.
    • Ottawa has also made COVID-19 vaccination mandatory for travel and federal public service employment.

In summary, the additional funding aims to ensure that those affected by vaccine-related injuries receive appropriate compensation while maintaining an impartial claims process. The program underscores the importance of vaccine safety and accountability in public health efforts. 


Comments